Osphos in horses

The safe use of OSPHOS has not been evaluated in horses less than 4 years of age or breeding horses. OSPHOS should not be used in pregnant or lactating mares, or mares intended for breeding. NSAIDs should not be used concurrently with OSPHOS. Concurrent use of NSAIDs with OSPHOS may increase the risk of renal toxicity and acute renal failure.

For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs recur

The safe use of OSPHOS has not been evaluated in horses less than 4 years of age or breeding horses. OSPHOS should not be used in pregnant or

Behance is the world's largest creative network for showcasing and discovering creative osphos horses work.

by E Verdecchia 2024Equine nsaids and analgesics. Navicular in horses. (2024). OSPHOS FAQs. (2024). OSPHOS (clodronate injection). (2024). Tildren - how it. (2024 ). Tildren

Of the 211 horses screened for enrollment, 146 horses received treatment (111 OSPHOS and 35 saline control). 29% of horses screened for enrollment were not eligible based on radiographic findings. 114 horses (86 OSPHOS, 28 saline control) were included in the statistical analysis. Effectiveness was evaluated on Day 56 post-treatment.

Of the enrolled horses, 111 were treated with OSPHOS Injection and 35 with a saline control. Lameness scores were recorded pre-treatment and on Study D and 180. There were 114 horses (86 OSPHOS Injection, 28 saline control) included in the statistical analysis.

FDA Provides Equine Veterinarians with Important Information about TILDREN and OSPHOS for Navicular. Syndrome in Horses;

Osphos Injection is an injectable bisphosphonate solution for intramuscular use in horses only. Active ingredients. Each Osphos Injection mL contains:.